Oppenheimer Asset Management Inc. bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 37,530 shares of the medical research company’s stock, valued at approximately $6,157,000.
Several other large investors have also recently modified their holdings of AMGN. Garde Capital Inc. increased its stake in shares of Amgen by 30.2% in the fourth quarter. Garde Capital Inc. now owns 2,284 shares of the medical research company’s stock valued at $334,000 after buying an additional 530 shares in the last quarter. Kentucky Retirement Systems purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $7,893,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $3,521,000. Searle & CO. purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $1,019,000. Finally, Opus Point Partners Management LLC increased its stake in shares of Amgen by 2.3% in the fourth quarter. Opus Point Partners Management LLC now owns 18,743 shares of the medical research company’s stock valued at $2,740,000 after buying an additional 421 shares in the last quarter. Institutional investors own 79.53% of the company’s stock.
Shares of Amgen Inc. (NASDAQ AMGN) traded up 0.48% during mid-day trading on Friday, hitting $169.93. The stock had a trading volume of 414,401 shares. The stock’s 50-day moving average is $174.60 and its 200-day moving average is $167.37. The firm has a market capitalization of $123.99 billion, a PE ratio of 15.48 and a beta of 1.35. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the firm earned $2.84 earnings per share. The business’s revenue was up 2.1% on a year-over-year basis. Equities analysts expect that Amgen Inc. will post $12.57 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 annualized dividend and a yield of 2.72%. Amgen’s dividend payout ratio is currently 41.93%.
AMGN has been the topic of several recent analyst reports. Cowen and Company restated an “outperform” rating and issued a $209.00 target price on shares of Amgen in a research note on Wednesday, April 19th. Sanford C. Bernstein restated a “market perform” rating and issued a $178.00 target price on shares of Amgen in a research note on Tuesday, April 25th. Robert W. Baird restated a “neutral” rating and issued a $165.00 target price on shares of Amgen in a research note on Friday, April 28th. Mizuho set a $195.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is currently owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.